Maharashtra FDA Cancels 10 Ayurvedic Licences

The Maharashtra Food and Drug Administration (FDA) has cancelled the manufacturing licences of 10 Ayurvedic drug manufacturers due to serious violations of Good Manufacturing Practices (GMP). This decision was made after a statewide inspection drive, which also resulted in show-cause notices being issued to 135 other manufacturers.

The inspection drive was conducted to ensure that all Ayurvedic manufacturers in the state are complying with the prescribed GMP and quality-control standards. FDA officials inspected manufacturing facilities, scrutinising technical manpower, quality-control systems, batch records, raw material and finished-product testing, SOPs, and other mandatory records.

The 10 units that had their licences cancelled were found to have serious lapses, including the absence of approved technical personnel, manufacturing without competent technical staff, non-functional quality-control departments, inadequate machinery and testing equipment, unhygienic premises, missing batch and raw-material records, incorrect manufacturing dates on labels, lack of testing records, and inadequate measures to prevent cross-contamination.

The cancelled licences include those of Krishna Herbal, Baramati; Lalshah Organic Products, Karanja, Gondia; Aditya Pharma and Angaras Ayurveda, Tiroda, Gondia; Kalidas Gandhi, Pune; Shivnath Ayurvedic Products Company, Sinnar; Inducare Pharma Pvt Ltd, Jejuri MIDC; Hakim Ayurvedic Beauty Care, Amravati; Hilarious Ayurveda, Gondia; and Yashoda Lab Pvt Ltd, Nashik Road.

FDA Commissioner Tukaram Mundhe stated that manufacturers must strictly comply with prescribed GMP and quality-control standards to ensure the safety, quality, and efficacy of Ayurvedic medicines. He warned that strict action will be taken against units violating the regulations.

The Maharashtra FDA has a total of 434 licensed Ayurvedic manufacturers in the state. The inspection drive and subsequent cancellation of licences and issuance of notices demonstrate the FDA's commitment to ensuring the quality and safety of Ayurvedic medicines in the state.

The cancellation of licences and issuance of notices to Ayurvedic manufacturers is a significant step towards regulating the industry and protecting public health. It highlights the importance of complying with GMP and quality-control standards in the manufacture of Ayurvedic medicines.

The FDA's actions are expected to have a positive impact on the industry, as they will help to build trust among consumers and ensure that only safe and effective Ayurvedic medicines are available in the market.

In conclusion, the Maharashtra FDA's decision to cancel the licences of 10 Ayurvedic drug manufacturers and issue notices to 135 others is a significant step towards regulating the industry and protecting public health. It emphasizes the importance of complying with GMP and quality-control standards and demonstrates the FDA's commitment to ensuring the safety, quality, and efficacy of Ayurvedic medicines in the state.

The move is also expected to boost the confidence of consumers in the Ayurvedic industry, as they can be assured that the medicines they are using are safe and effective. It will also encourage other manufacturers to comply with the regulations, leading to an overall improvement in the quality of Ayurvedic medicines available in the market.

Overall, the Maharashtra FDA's actions are a positive step towards regulating the Ayurvedic industry and protecting public health. They demonstrate the FDA's commitment to ensuring the safety, quality, and efficacy of Ayurvedic medicines and will help to build trust among consumers.

The cancellation of licences and issuance of notices to Ayurvedic manufacturers is a significant development in the industry, and it will be interesting to see how the industry responds to these actions. However, one thing is clear - the Maharashtra FDA is committed to ensuring the quality and safety of Ayurvedic medicines, and it will take strict action against any manufacturer that fails to comply with the regulations.

The FDA's actions are a reminder to all manufacturers in the industry that they must comply with the prescribed GMP and quality-control standards. Failure to do so can result in serious consequences, including the cancellation of licences and issuance of notices.

In the end, the Maharashtra FDA's decision to cancel the licences of 10 Ayurvedic drug manufacturers and issue notices to 135 others is a significant step towards regulating the industry and protecting public health. It emphasizes the importance of complying with GMP and quality-control standards and demonstrates the FDA's commitment to ensuring the safety, quality, and efficacy of Ayurvedic medicines in the state.